Singular Genomics

United States
San Diego, California, United States

Company profile

Singular Genomics company profile

Singular Genomics is a life science technology company that is leveraging novel, next generation sequencing (NGS) and multiomics technologies to build products that empower researchers and clinicians. The Singular Sequencing Engine is the foundational platform technology that forms the basis of Singular Genomics’ products in development and Singular Genomics’ core product tenets: accuracy, speed, flexibility and scale. Singular Genomics’ first integrated solution is targeted at the NGS market and comprises an instrument and an associated menu of consumable kits, which Singular Genomics refers to collectively as the G4 Integrated Solution. A second integrated solution in development comprises an instrument and an associated menu of consumable kits, which Singular Genomics refers to collectively as the PX Integrated Solution. The PX Integrated Solution combines single cell analysis, spatial analysis, genomics and proteomics in one integrated instrument providing a versatile multiomics solution.

Business identity

Contact email
[email protected]
Operating status
Active
Company type
For Profit
Employee range
101-250 employees
Revenue range
$0-$1M
Founded
2016-01-01, Year

Headquarters

Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
M And A
Funding rounds
3
Total equity funding
$45.5M
Last funding
Convertible Note / $130.5M / 2021-05-12
Last equity funding
Series B / $45.5M
Investors
9
Lead investors
1
Founders
2
Articles
64
Exited on
2021-05-27

Founders and investors

Founders

Drew SpaventaEli Glezer

Lead investors

F-Prime

Investors

CoatueDeerfieldF-PrimeRevelation PartnersS32